Adjuvant Nivolumab versus Ipilimumab in Resected Stage III or IV MelanomaJeffrey S. Weber, Paolo A. Ascierto, Victoria Atkinson et al.|New England Journal of Medicine|2017Cited by 2.2k
Ipilimumab 10 mg/kg versus ipilimumab 3 mg/kg in patients with unresectable or metastatic melanoma: a randomised, double-blind, multicentre, phase 3 trialPaolo A. Ascierto, Michele Maio, Michele Del Vecchio et al.|The Lancet Oncology|2017Cited by 501
Adjuvant therapy with nivolumab (NIVO) versus ipilimumab (IPI) after complete resection of stage III/IV melanoma: Updated results from a phase III trial (CheckMate 238).Jeffrey S. Weber, Paolo A. Ascierto, Mario Mandalà et al.|Journal of Clinical Oncology|2018Cited by 75
Bempegaldesleukin Plus Nivolumab Versus Sunitinib or Cabozantinib in Previously Untreated Advanced Clear Cell Renal Cell Carcinoma: A Phase III Randomized Study (PIVOT-09)Nizar M. Tannir, Oleg Karyakin, Maria Nirvana Formiga et al.|Journal of Clinical Oncology|2024Cited by 26
Overall survival (OS) and safety results from a phase 3 trial of ipilimumab (IPI) at 3 mg/kg vs 10 mg/kg in patients with metastatic melanoma (MEL)Paolo A. Ascierto, Michele Maio, Michele Del Vecchio et al.|Annals of Oncology|2016Cited by 23